US › Healthcare

Xenetic Biosciences Inc (XBIO)

US · Healthcare · Biotechnology

$2.46+12.33%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$660,601

Revenue YoY

+12.0%

Net profit

$-929,695

EPS

$-0.41

Net margin

-140.7%

Key statistics

Market cap

$9.5M

Forward P/E

0.0

P/B

1.63

Book value

$3.23

EPS (TTM)

$-1.15

52-week high

$13.93

52-week low

$1.90

50-day MA

$3.21

200-day MA

$2.82

Beta

2.24

Analyst view

Analysts rate Xenetic Biosciences Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $40.00.

Shareholding

Insiders

15.42%

Institutions

6.49%

Largest institutional holders

Fund	Stake
Renaissance Technologies Corp	6.00%
Geode Capital Management, LLC	0.94%
Vanguard Capital Management, LLC	0.29%
JTC Employer Solutions Trustee Ltd	0.12%
Tower Research Capital LLC	0.04%
Harwood Advisory Group, LLC	0.00%
DRW Securities, LLC	0.00%
Morgan Stanley - Brokerage Accounts	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Xenetic Biosciences Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.